AIRS stock forecast, quote, news & analysis
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices... Show more
Why AirSculpt Technologies (AIRS) Is Up +57% in the Last 30 Days
Key Takeaways
- AIRS stock rose +57% over the last 30 days from $1.74 to $2.73, driven by a mid-March surge following preliminary Q4 revenue disclosure and insider buying despite a filing delay.
- Over the past quarter, the stock gained +48% from $1.85 to $2.73, amid volatile trading linked to revenue weakness but offset by marketing improvements and positive February same-store trends.
- Preliminary FY2025 revenue fell 16% to $152 million due to lower case volumes, with net losses widening; refreshed marketing showed early signs of stabilization.
- Analyst price targets average $6.00, suggesting upside potential amid current undervaluation perceptions.
- Strong liquidity with $13 million cash supports balance sheet amid debt reduction efforts.
AirSculpt Technologies (AIRS) Company Overview and Market Position
AirSculpt Technologies, Inc. (AIRS) is a leading provider of minimally invasive body contouring procedures, operating under the Elite Body Sculpture brand. The company offers proprietary AirSculpt treatments that remove fat and tighten skin without general anesthesia, including AirSculpt+, AirSculpt Smooth for cellulite, and specialized fat transfer options like Power BBL (Brazilian butt lift), Up a Cup (breast enhancement), and Hip Flip (hourglass contouring). Headquartered in Miami Beach, Florida, and founded in 2012, AIRS serves patients across centers in the United States, Canada, and the United Kingdom.
Its business model relies on a network of centers delivering premium, physician-led procedures with high revenue per case, emphasizing patient financing and marketing for demand generation. In the competitive medical aesthetics industry, AIRS differentiates through its patented technology and consumer-focused experience, though it faces headwinds from economic sensitivity in elective procedures. Recent revenue softness highlights vulnerability to discretionary spending, but fundamentals like improving same-store revenue signal resilience.
AirSculpt Technologies (AIRS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AIRS stock climbed +57%, from a close of $1.74 on March 3, 2026, to $2.73 on April 1, 2026. The movement was highly volatile, with a sharp rally starting March 13 from $1.85 to a peak of $3.25 on March 26—up over 75% intraday—before pulling back amid profit-taking. Trading volume spiked dramatically, reflecting heightened investor interest.
For the past quarter, shares advanced +48%, from $1.85 on January 2, 2026, to the current $2.73. The period featured range-bound trading in January-early March around $1.80-$3.00, punctuated by the late-March surge. Overall, the uptrend was trend-driven but erratic, influenced by company news amid broader healthcare sector dynamics.
What Drove AIRS Stock Price in the Last 30 Days
The 30-day rally stemmed primarily from AirSculpt's March 16 announcement of preliminary FY2025 results and intent to delay its 10-K filing due to inter-company balance reviews. Despite disclosing weaker Q4 revenue of $33.4 million (down 15% year-over-year) and FY revenue of $151.8 million amid 16% same-store declines, the update noted positive February same-store growth from a refreshed marketing strategy and Q1 2026 guidance of $38.5-$39.5 million (flat same-store at midpoint). Investors reacted positively to stabilization signals, propelling shares up 47% on March 16 alone with massive volume.
Subsequent insider and major shareholder purchases in mid-March signaled confidence, further boosting sentiment. Analyst notes highlighted undervaluation versus $6.00 targets, while short interest dynamics added squeeze potential. Sector sentiment in medical aesthetics supported the move, though volatility persisted post-peak.
What Drove AIRS Stock Performance Over the Last Quarter
The quarterly gain reflected a turnaround narrative amid persistent challenges. Earlier weakness tied to Q3 2025 results in November, showing 18% revenue drop to $35 million on lower case volumes (down 15%), prompting guidance cuts and net losses. Macro factors like inflation-hit consumer spending on elective procedures pressured demand, with FY2025 revenue ultimately down 16%.
Improvement emerged via debt paydown ($10 million in June 2025), leadership changes (new CEO in December 2024, Chairman in November 2025), and marketing refresh yielding February positivity. Institutional accumulation and high short interest (over 130% of float) fueled rebounds. Cumulative impact: operational tweaks outweighed revenue headwinds, driving the net uptrend despite volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from among hundreds that analyze and trade thousands of stock tickers across various markets. These curated bots employ diverse strategies—such as trend-following, mean reversion, or momentum plays—spanning short-term scalping to longer-term positions, with performance metrics like win rate, profit factor, and Sharpe ratio prominently displayed. Updated in real-time based on recent results and relevance, the section helps traders identify bots suited to current market trends or specific assets like AIRS. Explore the page to discover high-alpha opportunities and potentially enhance your trading with data-backed automation.
AIRS Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor the full FY2025 10-K filing details on inter-company issues and audited financials, alongside Q1 2026 earnings for confirmation of same-store stabilization. Track marketing effectiveness via monthly case volumes and revenue per case trends. Macro conditions like consumer confidence and interest rates will influence elective procedure demand. Upcoming catalysts include new center openings, potential partnerships, or further debt reduction; risks encompass prolonged softness in aesthetics spending or regulatory scrutiny on financing. Analyst updates and institutional flows remain key sentiment indicators.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Momentum Indicator for AIRS turns negative, indicating new downward trend
AIRS saw its Momentum Indicator move below the 0 level on June 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 70 similar instances where the indicator turned negative. In of the 70 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for AIRS moved out of overbought territory on June 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for AIRS turned negative on June 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AIRS broke above its upper Bollinger Band on May 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 51 cases where AIRS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AIRS advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 190 cases where AIRS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AIRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.574) is normal, around the industry mean (219.600). P/E Ratio (196.563) is within average values for comparable stocks, (120.535). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.438). AIRS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (2.114) is also within normal values, averaging (2.487).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement